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were found to result in a variability below 5% in parameters measured di-
rectly from the average waveform, and up to 10% in those obtained from
the time derivative. Subsequently, the feasibility of an automated version of
the algorithm, based on objective operator independent criteria, was evalu-
ated, and parameters obtained were found to be in excellent agreement with
those obtained using manual approach. In summary, this algorithm provides
a fast. easy and objective method for noise reduction in acoustic quantifica-
tion signals. This algorithm may improve the on-line noninvasive assessment
of systolic and diastolic LV function.
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1741-1 1 Clinical Experience with Heparin-Coated Stents -
The Benestent II Pilot Phase 1
H~kan Emanuelsson, Patrick W. Serruys, Jorge Belardi, Hans Bonnier,
Antonio Colombo, Jean Fajadet, Jean-Jacques Goy, Guy Heyndrickx, Peter de
Jaegere, Victor Legrand, Cadas Macaya, Pierre Materne, Wolfgang Rutsch,
Ulrich Sigwart, Harry Suryapranata, enestent Study Group. Division of Cardiology,
Sahlgrenska Hospital, G6teborg, Sweden; Thoraxcenter, Erasmus Univ. Rotterdam, The
Netherlands
Krzysztof P. Wr6blewski, Zhi Yun Tian. Children's Hospital ofPhiladelphia,
Philadelphia, PA
Congenital heart disease (CHD) is the most common congenital malforma-
tion with an incidence rate of 0.7%. Many pregnant woman (in some coun-
tries all) are offered an ultrasound scan at around 18 weeks of pregnancy.
The scan incorporates a detailed anatomical survey of the fetus and if in-
cludes at least a four chamber view, it is an excellent opportunity to detect
congenital heart defects. Therefore a Windows based multimedia computer
program for the instruction of Fetal Echo for ultrasound technologists, stu-
dents. residents, fellows and primary care physicians has been developed.
The application includes a step by step tutorial to instruct the user in reading
Fetal Echo data, a browsing library of definitions of CHD's, graphics images
and digitized echocardiograms, and the Expert System for automatic diagno-
sis. The pictures, images and descriptions are linked to a database and can
be viewed by searching for the defect name or symptoms. This provides a
powerful instructional tool in this very difficult area of medical education.
The minimum hardware requirements to run this program are: IBMIPC or
compatible computer running MS Windows version 3.1 with 80386SX pro-
cessor,4 MB RAM, 30 MB free disk space, multimedia with dual speed CD
ROM, and a VGA card capable to display at least 256 colors.
Steven Georgeson. Somerset Medical Center, Somerville, NJ
The differentiation between atrioventricular reciprocating tachycardia via an
accessory pathway (AVRT). AV nodal reentrant tachycardia (AVNRT) and atrial
tachycardia (AT) in paroxysmal supraventricular tachycardia may be helpful
in guiding pharmacologic therapy and in identifying patients for radiofre-
quency catheter ablation. To help in this differentiation, an expert system
was developed using a commercially-available expert system shell (EXSl'S).
A simplified version of this system was designed to run on a palm-top com-
puter. Both programs use the MS-DOS operating system. The expert system
is rule-based and assigns probability values to the goal states through the
process of backward chaining. The goal states for this expert system were
AVRT, AVNRT, and AT. The user is queried for the presence of various abnor-
malities on the presenting EKG (P wave location, ORS alternans, pseudo r
wave in lead V1, pseudo S wave in the inferior leads), comparison with pre-
vious EKG's (presence of pre-excitation) and the effect of vagal manueuvers
or adenosine infusion on the tachycardia. From published data, each abnor-
mality is assigned a probability based on the positive predictive value of the
abnormality for AVRT, AVNRT and AT. By combining the positive predictive
values, the expert system assigns a final probability for AVRT, AVNRT and AT.
This expert system may be useful as a diagnostic tool and a teaching aid
in the differentiation between AVRT, AVNRT and AT in paroxysmal supraven-
tricular tachycardia.
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Full Antiplatelet Therapy without Anticoagulation
After Coronary Stenting
The purpose of the Benestent II Pilot Phase was to explore the safety of
reducing antithrombotic therapy in conjunction with implantation of heparin-
coated stents. The study consists of three phases, where resumption of hep-
arin therapy after stent implantation was progressively delayed in a stepped
care approach.
Material and Methods. Palmaz-Schatz stents with heparin coating were
implanted in 51 patients (88% male) with stable angina pectoris. Heparin
treatment was withheld 6 hours following removal of the sheath introducer
from the femoral artery. The mean age was 59 years, 10% had a previous
myocardial infarction, diabetes was prevalent in 8%, hypertension in 24%
and 59% were current or previous smokers. Target lesion was located in
the left anterior descending artery in 51 %, left circumflex in 8% and right
coronary artery in 41 %. TIM I flow I-II was present in 14% and TIMIIlI in 86%.
The mean pre-procedural minimal lumen diameter (MLD) was 1.10 mm and
reference diameter 3.16 mm.
Results. Stent implantation was successful in all patients and following the
procedure, mean MLD increased to 2.77 mm and percent diameter stenosis
was reduced from 65% to 19%. The maximum balloon size was 3.45 ± 0.40
mm. Post-stent dilatation was performed in 40 patients (80%). High pressure
(> 12 atm) was used in 22 of these cases (54%). Two patients needed a sec-
ond stent· one for an occlusive distal dissection and one for a distal lesion.
There we;e no major complications, i.e. death, myocardial infarction, urgent
CABG, re-PTCA or cerebrovascular accident. Peripheral vascular complica-
tions required vascular surgery in 3 patients (5.9%) and blood transfusion in
one (2%).
Conclusions. In this pilot study implantation of heparinized stents was as-
sociated with a 100% success rate, absence of serious complications and
a moderate incidence of vascular complications. Further reduction of an-
tithrombotic treatment may be feasible.
Jean-Marc Lablanche, Gilles Grollier, Nicolas Danchin, Jean-Louis Bonnet, Eric Van
Belle, Eugene Me Fadden, Michel E. Bertrand. Universib'esofUlle, Caen, Nancy and
Marseille, France
Subacute thrombosis remains a major limitation of coronary stenting. In addi-
tion, local complications related to the intensive anticoagulation that is com-
monly employed are frequent.
We prospectively studied a regime of intensive antiplatelet therapy (as-
pirin 200 mg daily begun before percutaneous transluminal coronary angio-
plasty, ticlodipine 500 mg daily for 3 months begun just after angioplasty)
with periprocedural dextran infusion continued for a period at the discretion
of the local investigator. To date, 98 patients (85 men, 13 women) undergo-
ing 102 procedures involving 125 stents have been enrolled; 71 patients had
one stent implanted; 19 patients had 2 stents implanted, and 2 patients had
3 stents implanted. Symptoms before coronary angioplasty included effort
angina (23%), angina at rest (6%), unstable angina (23%), recent myocardial
infarction (27%). The indications for stent implantation were occlusive dis-
section 36%, dissection without occlusion 32%, suboptimal result or elec-
tive implantation 32%. The stented site was the LAD (37%). RCA (35%). LCx
(17%), and vein graft (11 %). Stent types were Wiktor (70%), Palmaz-Schatz
(23%). Gianturco-Roubin (7%). The diameter of the stents implanted was 2.5
mm (2%), 3.0 mm (32%), 3.5 mm (44%), and 4.0 mm (22%). There were 2
deaths; 1 patient died from cardiogenic shock that was present before stent
implantation 1 patient commited suicide; 4 patients developed q-wave AMI,
1 was already complete at the time of stent implant. 3 occurred In the hours
after stent implant for occlusive dissection; 8 patients had non-O AMI; 3 pa-
tients had CABG, 1 at 5 hours post stent for reocclusion (non-O wave AMI).
2 were performed electively without sequelae for an unsatisfactory angio-
graphic result but without ongoing ischemia. Blood transfusion for peripro-
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cedural blood loss was needed in 2 patients. No coronary event occurred
between 48h and discharge, or during follow-up. Local complications oc-
curred in 4 patients (surgical repair 1, blood transfusion 2, false aneurysm
1)
In this early experience, no subacute closure occurred after bailout or elec-
tive stenting using intense antiplatelet therapy. Such an approach appears
safe and may permit much earlier patient discharge.
with external compression and 3 minor hemotomas. Mean hospital stay was
2 ± 2 days.
Conclusions. (1) Protamine given immediately following a successful stent
implantation with optimal stent expansion confirmed by IVUS did not cause
stent thrombosis. 12) The results of this small cohort would support the
feasability of using protamine to facilitate sheath removal and hospital dis-
charge in selected patients after stent implantation assisted by IVUS.
Percutaneous Trans Radial Coronary Stenting
without Coumadin can Reduce Vascular Access
Complications and Hospital Stay
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1741-51 Improved Post Stent Management: High Gain at Low
Risk
P. Buszman, J. Clague, S. Gibbs, N. Buller, C. Knight. P. Groves, U. Sigwart. Royal
Brompton Hospital, Sydnay Straat London UK.
Prolonged hospital stay, sophiscated anticoagulation and a high number of
local puncture site complications are the reasons why coronary stenting, de-
spite its attractive immediate and long term results, is not yet fully accepted.
We have tested in 100 consecutive patients a simplified post implant man-
agement designed to shorten hospital stay without increasing the risk of
subacute thrombosis or bleeding complications. The decision for stenting
was always made during angioplasty. There were no preselected cases. All
patients had suboptimal results due to elastic recoil or type 2 to 3 dissec-
tions. A total of 123 Johnson &Johnson PS-153 stents (24 half stents, 87 full
stents and 12 tandem stents) were implanted using high pressure balloons
with implantation pressures exceeding 14 bar. The mean reference vessel
diameter was 3.2 ± 0.6 mm final balloon size at maximum pressure was 3.4
± 0.3 mm. In 73% of the stent implants a short balloon was used for the final
dilation. Only in 10 patients was the procedure complimented by intravascu-
lar ultrasound. The ACT at the time of implant was 346 ± 48 seconds, no
further intravenous heparin was given. All sheaths were removed the same
day and a FemoStop'" compression device was left in situ at low pressures
for 8 ± 3.5 hours. The patients were discharged on day 1 (48 patients) or 2
(52) on low molecular weight heparin 5,000 units SC for 7 days, self admin-
istered after instruction. Warfarin was started the day of the procedure and
given for 6 weeks and regulated to an INR of 2.5 to 3.5 while the patient was
out of hospital. All patients received Aspirin 75 mg per day and a calcium
antagonist.
There was 1 subacute thrombosis which was successfully treated by
thrombolysis at 16 hours after implant secondary to a non covered distal
dissection. We observed 1 femoral false aneurysm responding to compres-
sion. 1 patient died 10 days after the procedure from late haemorrhage due
to dissection of the iliac artery.
We conclude that a short hospital stay does not increase the risk of throm-
botic and bleeding complications after stenting. Stenting with good primary
result has a extremely low subacute thrombosis rate. Intravenous heparin
after stenting is unnecessary.
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Paul Barragan, Marc Silvestri, Joel Sainsous, Jean-B. Simeoni, Gilles Bayet,
Jean-L. Bouvier, Bertrand Comet. Cliniqua "Las AJpillas~ Marsailla, France
Intravascular ultrasound (IVUS) guiding optimal coronarystent expansion has
been proposed in the prevention of subacute stent thrombosis (SIT) wich
remains the major limitation of coronary stenting. However this strategy, re-
quiring high balloon pressure, enhances the risk of coronary rupture, and
increases the time of procedure. We report our experience of coronary stent-
ing using quantitative coronary analysis (OCA) and ticlopidine regimen (500
mg/day) initiated 3 days before PTCA and given for one month after stenting
without any anticoagulation. From March 1994 to July 1994 among 587 con-
secutive PTCA, 208 patients (63 ± 11 yrs) were successfully stented on 235
lesions with 248 stents (223 Palmaz-Schatz, 25 Gianturco-Roubin). Femoral
approach was used in 98% of cases with 8F (65%) or 6F guiding catheter
(35%). Indications for stenting were elective (70%) or after failed PTCA(30%).
The stents were expanded with a non compliant balloon (final diameter =
3.46 ± 0.42 mm) at 10 bars. OCA results were:
11 :00
Prevention of Subacute Occlusion After Coronary
Stenting with Ticlopidine Regimen without
Intravascular Ultrasound Guided Stenting
* p < 0.001
One month major complications included 2 deaths (0.96%1. 2 O-wave
MI (0.96%) and 1 emergency CABG (0.5%). SST during the first month oc-
cured in 1 pt (0.5%). One pt (0.5%) required external compression for false
aneurism and one (0.5%) blood transfusion for gastric hemorrhage.
Conclusion: Pre and post coronary stenting treatment with ticlopidine reg-
imen provides low rate of SST with acceptable vascular bleeding complica-
tions. Routine IVUS utility with this regimen remains uncertain.
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Preliminary Experience Using Protamine to Reverse
Heparin Immediately Following a Successful
Coronary Stent Implantation
Antonio Colombo, Patrick Hall, Shigeru Nakamura, Luigi Maiello, Brenda Hann,
Simonetta Slengino, Giovanni Martini, Leo Fincr. Columbus Hospital, Milan, Italy
Previous reports have documented the safety of the treatment only with an-
tiplatelet therapy and no subsequent anticoagulation following stent implan-
tation with optimal stent expansion confirmed by intravascular ultrasound
(IVUS). More recently, protamine has been used in selected patients after a
successful stent implantation procedure to decrease hematoma formation,
and to facilitate early sheath removal and hospital discharge. Lesions were
selected on the basis of an optimal angiographic and IVUS result and unim-
paired distal runoff. The cohort includes 30 consecutive patients (pts) with 37
lesions (les) that received protamine following a successful stent implanta-
tion. All pts were subsequently treated only with antiplatelet therapy and no
subsequent anticoagulation. The mean age was 58 ± 11. Indication for stent
implantation was elective in 32 les (90%) and emergency for threatened clo-
sure in 5 lesions (10%). Vessel distribution was 15 LAD (41 %1. 15 RCA(41 %),
6 LCX (16%), and 1 Left Main (3%). Lesion location was 22 proximal (59%),
11 mid/distal (41%).51 stents (39 Palmaz-Schatz, 9 Gianturco-Roubin, and 3
Wiktor) were used for afl average of 1.4 ± 0.7 stentsllesion. The protamine
dose was 41 ± 20 (range 12.5 mg to 50 mg). ACT priorto protamine was 300
± 69 (range 185 to 481). Angiographic (AG) and IVUS results are below:
Proximal Lesion Stenosis Distal
Reference or Stent ('!o) Reference
Baseline AG (mm) 3.10 ± 0.50 0.92 ± 0.053 ( 72 ± 16) 298 ± 048
Post Stent AG (mm) 319±042 3.04 ± 048 ( -2 ± 13) 3.06 ± 048
IVUS Lumen (mm2 ) 9.3 ± 3.0 7.6 ± 1.6 7.1 ±24
Jean Fajadet. Christian Jordan, Henrique Carvalho, Bernard Cassagneau,
Gabriel Robert, Jean-Pierre Laurent. Yves Siboni, Jean Marco. Cliniqua Pastaur.
Toulouse, France
Benestent and Stress studies have demonstrated that the significant reduc-
tion of restenosis rate after Palmaz-Schatz stent(S) implantation of de novo
lesions was associated with a longer hospital stay and a higher bleeding
and vascular access complication rate due to the intensive anticoagulation.
Therefore we have studied a new coronary stenting procedure using a 6F
transradial approach and a new protocol based on antiplatelet drug combi-
nation (Aspirin = 250 mg/day ± Ticlopidin 500 mg/day), low molecular weight
heparin and no Coumadin. One hundred and nineteen patients (101 males,
18 females, with a mean age of 61.8 ± 11.6 yrs (32-83) received 154 S in
127 vessels. Stenting was elective in 38% and non elective in 62%. No acute
thrombosis occurred. Two major cardiac events were observed: one pt with
low LVEF (37%1 and 3 vessel disease presented a sudden death 3 days after
non elective LAD stent implantation and one pt had a non O-wave MI due to
a side branch occlusion after non elective stenting. The 118 pts discharged
2.9 ± 1.5 days (1-8 days) after procedure and 75% of them within the first 3
days. Conclusion: Trans radial coronarystenting is a safe and effective proce-
dure. This new stent delivery procedure can certainly reduce vascular access
complications and hospital stay.
There were no acute or subacute stent thrombosis events at 1 month clin-
ical follow up. Vascular complications included 1 pseudoaneuysm treated
